Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The top 5 metabolites in terms of absolute correlation coefficient with the abundance of Alistipes were Lithocholate sulfate, 5’-Butyrylphosphoinosine, p-Acetamidophenol, Calcitriol, and 3-(6-Aminopurin-9-yl)-5-(hydroxymethyl) cyclopentane-1,2-diol.

Source: Correlation analysis between gut microbiota and intestinal tissue metabolites. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Animal research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

All mice were acclimated to the environment under the same conditions for 7 days, then randomly divided into 6 groups using a computer-generated random number table (n = 8 per group) to ensure that there was no systematic bias in initial body weight and health status among the treatment groups.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Regulatory effects of berberine on intestinal microecology in mice with ulcerative colitis

Study design awaiting verification · Frontiers in Microbiology · 2025

Original publication title

Regulatory effects of berberine on intestinal microecology in mice with ulcerative colitis

Xinyi Xu; Bin Zhao; Pingyu Liu; Xiaohui Tang; Zonglang Lai; Na Song; Jun Cheng

Copyright © 2025 Xu, Zhao, Liu, Tang, Lai, Song and Cheng.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Berberine ameliorates symptoms of UC in mice by regulating gut microbiota and metabolite composition. MR analysis first establishes a unidirectional causal chain of PDGFA/lithocholate sulfate/Alistipes, and animal experiments confirm that blocking the PDGFA receptor reverses its therapeutic effects and aggravates inflammation and intestinal mucosal injury.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Currently, therapeutic approaches for ulcerative colitis (UC), such as aminosalicylates, glucocorticoids, and biologics, exhibit certain efficacy but are hindered by limitations including side effects, high costs, or suboptimal responses. As a traditional Chinese medicine component, berberine (BBR) possesses anti-inflammatory properties and the ability to modulate the gut microbiota, with low toxicity, and may provide new directions for UC treatment in the future.

Source: Background

Abstract: What methods does the paper describe?

A mouse UC model was established via dextran sulfate sodium (DSS) induction, and dose-and time-dependent screening was performed to determine the optimal BBR dosage and intervention duration for subsequent experiments. The disease activity index (DAI) and colon length were measured. Colonic tissue changes were observed via HE staining. Serum cytokine levels (IL-1β, TNF-α, IL-10, TGF-β) were detected using ELISA. The expression levels of ZO-1 and Occludin in mouse colonic tissues were detected by WB.

Further analyses included 16S rRNA sequencing to assess gut microbiota diversity and composition, untargeted metabolomics to identify differential metabolites in intestinal tissues, and Mendelian randomization (MR) analysis to explore causal associations among intestinal genes, circulating metabolites, and key bacterial genera. Finally, functional validation was performed by inhibiting the PDGFA receptor.

Source: Methods

Abstract: Results

Berberine significantly alleviated the DAI score, colonic pathological damage, and cytokine imbalance in UC mice, as well as restored mucosal barrier integrity, with the most pronounced effects observed in the UC + low-BBR 14 days group. Gut microbiota analysis revealed distinct microbial structures across groups, with the UC + low-BBR 14 days group showing significantly higher relative abundances of Bacteroides, Alistipes, and unclassified_Clostridia_vadinBB60_group compared to the UC group (p < 0.05). Metabolomics analysis indicated that berberine altered the composition of intestinal tissue metabolites and metabolic pathways.

MR analysis demonstrated inverse causal associations between PDGFA and lithocholate sulfate, as well as between lithocholate sulfate and Alistipes. Additionally, inhibition of the PDGFA receptor reversed the therapeutic effects of BBR, exacerbating inflammatory responses and intestinal mucosal barrier damage. Finally, the correlation analysis between gut microbiota and metabolites also confirmed that the abundance of the genus Alistipes exhibited a highly significant negative correlation with lithocholate sulfate levels (p < 0.001).

Source: Results

Abstract: Conclusion

Berberine ameliorates symptoms of UC in mice by regulating gut microbiota and metabolite composition. MR analysis first establishes a unidirectional causal chain of PDGFA/lithocholate sulfate/Alistipes, and animal experiments confirm that blocking the PDGFA receptor reverses its therapeutic effects and aggravates inflammation and intestinal mucosal injury.

Source: Conclusion
Authors’ abstract

Background

Currently, therapeutic approaches for ulcerative colitis (UC), such as aminosalicylates, glucocorticoids, and biologics, exhibit certain efficacy but are hindered by limitations including side effects, high costs, or suboptimal responses. As a traditional Chinese medicine component, berberine (BBR) possesses anti-inflammatory properties and the ability to modulate the gut microbiota, with low toxicity, and may provide new directions for UC treatment in the future.

Methods

A mouse UC model was established via dextran sulfate sodium (DSS) induction, and dose-and time-dependent screening was performed to determine the optimal BBR dosage and intervention duration for subsequent experiments. The disease activity index (DAI) and colon length were measured. Colonic tissue changes were observed via HE staining. Serum cytokine levels (IL-1β, TNF-α, IL-10, TGF-β) were detected using ELISA. The expression levels of ZO-1 and Occludin in mouse colonic tissues were detected by WB.

Further analyses included 16S rRNA sequencing to assess gut microbiota diversity and composition, untargeted metabolomics to identify differential metabolites in intestinal tissues, and Mendelian randomization (MR) analysis to explore causal associations among intestinal genes, circulating metabolites, and key bacterial genera. Finally, functional validation was performed by inhibiting the PDGFA receptor.

Results

Berberine significantly alleviated the DAI score, colonic pathological damage, and cytokine imbalance in UC mice, as well as restored mucosal barrier integrity, with the most pronounced effects observed in the UC + low-BBR 14 days group. Gut microbiota analysis revealed distinct microbial structures across groups, with the UC + low-BBR 14 days group showing significantly higher relative abundances of Bacteroides, Alistipes, and unclassified_Clostridia_vadinBB60_group compared to the UC group (p < 0.05). Metabolomics analysis indicated that berberine altered the composition of intestinal tissue metabolites and metabolic pathways.

MR analysis demonstrated inverse causal associations between PDGFA and lithocholate sulfate, as well as between lithocholate sulfate and Alistipes. Additionally, inhibition of the PDGFA receptor reversed the therapeutic effects of BBR, exacerbating inflammatory responses and intestinal mucosal barrier damage. Finally, the correlation analysis between gut microbiota and metabolites also confirmed that the abundance of the genus Alistipes exhibited a highly significant negative correlation with lithocholate sulfate levels (p < 0.001).

Conclusion

Berberine ameliorates symptoms of UC in mice by regulating gut microbiota and metabolite composition. MR analysis first establishes a unidirectional causal chain of PDGFA/lithocholate sulfate/Alistipes, and animal experiments confirm that blocking the PDGFA receptor reverses its therapeutic effects and aggravates inflammation and intestinal mucosal injury.

Publication and source details

Original title: Regulatory effects of berberine on intestinal microecology in mice with ulcerative colitis

Xinyi Xu; Bin Zhao; Pingyu Liu; Xiaohui Tang; Zonglang Lai; Na Song; Jun Cheng

Frontiers in Microbiology · 2025

* Correspondence: Na Song, songna896600@163.com; Jun Cheng, 13206075951@163.com
†

These authors have contributed equally to this work and share last authorship

Copyright © 2025 Xu, Zhao, Liu, Tang, Lai, Song and Cheng.2025Xu, Zhao, Liu, Tang, Lai, Song and Chenghttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Special Project of Performance Incentive Guidance for Scientific Research Institutions in Chongqing stc2021Mli30020 Chongqing Medical Scientific Research Project (Joint Project of Chongqing Health Commission and Science and Technology Bureau) 2021ZY014268 Joint Project of Jiangbei District Health Commission and Science and Technology Bureau JBKW2022zy002The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the Special Project of Performance Incentive Guidance for Scientific Research Institutions in Chongqing (No. stc2021Mli30020), the Chongqing Medical Scientific Research Project (Joint Project of Chongqing Health Commission and Science and Technology Bureau) (No. 2022ZDXM036), and the Joint Project of Jiangbei District Health Commission and Science and Technology Bureau (No. JBKW2022zy002).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:41:28.878735+00:00

DOI: 10.3389/fmicb.2025.1649947 · PMC12647005